ProStrakan launches cancer drug Abstral in Canada
Borders-based pharmaceutical firm ProStrakan has launched its cancer pain drug Abstral in Canada.
The drug will be sold by Prostrakan's Canadian partner, Paladin Labs.
Abstral rapidly melts under the tongue and is used to stop breakthrough pain in cancer patients who are already taking pain-relief drugs.
Prostrakan, which is based in Galashiels, was sold to a Japanese firm earlier this year and was launched earlier this year in the United States.
Abstral is already marketed by ProStrakan across Europe.